Evaluating CAR T-Cell Therapy Use – OncLive
|
Evaluating CAR T-Cell Therapy Use
OncLive And we’ve used the strategy of rescuing patients who are having progressive disease during the early phases of CAR T-cell therapy while there’s actually expansion of T cells in the blood. Interestingly, what we’ve seen is expansion in patients who … |
FierceBiotech |
Parkinson’s startup Prevail raises $75M for gene therapy programs
FierceBiotech OrbiMed-backed Prevail Therapeutics has launched a $75 million first-round financing that will help fund development of its gene therapy for Parkinson’s disease (PD) and other programs. Prevail was set up last year by OrbiMed’s co-head of private … Prevail Gets $75M For Parkinson’s Gene Therapy, Bolstering NY BiotechXconomy Prevail grabs $75MA round in the hunt for new gene therapies to stop the destruction caused by Parkinson’sEndpoints News Prevail Therapeutics Announces $75 Million Series A Financing to Advance Gene Therapies for Patients with …Business Wire (press release) |
|
Bavarian Nordic Announces Phase 2 Trial Investigating …
GlobeNewswire (press release) COPENHAGEN, Denmark, March 8, 2018 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced a new Phase 2 study, exploring the combination of its cancer vaccine, CV301 and Bristol-Myers Squibb’s nivolumab (OPDIVO®) in patients with metastatic … |
Genetic Literacy Project |
Digitizing DNA: Real reasons to worry about cyberbiosecurity
Genetic Literacy Project We’ve even hosted FBI agents from the Weapons of Mass Destruction Directorate here at Colorado State University and previously at Virginia Tech for crash courses on synthetic biology and the associated cyberbiosecurity risks. A year ago, we … |